目的 探讨心通口服液联合吲哚布芬治疗冠心病心绞痛的临床疗效。方法 选取2023年5月—2024年10月在河北中石油中心医院治疗的冠心病心绞痛患者122例，按随机数字表法将患者分为对照组和治疗组，每组各61例。对照组口服吲哚布芬片，0.1 g/次，2次/d。在对照组基础上，治疗组饭后口服心通口服液，10 mL/次，3次/d。两组患者疗程均为4周。观察两组患者临床疗效，比较治疗前后两组患者心绞痛发作次数、疼痛VAS评分、发作持续时间、心电图ST-T改善率，血瘀证、临床结局评价（CHD-PRO）和西雅图心绞痛量表（SAQ）评分，及凝血酶时间（TT）、国际标准化比值（INR）、血小板聚集率（PAR）、D-二聚体（D-D）和超敏-C反应蛋白（hs-CRP）水平。结果 治疗后，治疗组总有效率为95.08%，明显高于对照组（83.61%，P＜0.05）。治疗后，两组心绞痛发作次数、疼痛VAS评分、发作持续时间均低于组内治疗前（P＜0.05），且治疗组明显低于对照组（P＜0.05）。治疗后，治疗组心电图ST-T改善率（85.25%）明显高于对照组（70.49%，P＜0.05）。治疗后，两组患者血瘀证评分都低于组内治疗前，而CHD-PRO、SAQ评分高于治疗前（P＜0.05），且治疗后治疗组各评分明显好于对照组（P＜0.05）。治疗后，两组TT、INR均高于组内治疗前，而PAR和血浆D-D、hs-CRP水平都低于组内治疗前（P＜0.05），且治疗组凝血指标、PAR和血浆D-D、hs-CRP水平明显好于对照组（P＜0.05）。结论 针对冠心病心绞痛联合使用心通口服液与吲哚布芬，安全性较好，能有效缓解患者心绞痛症状，改善血瘀状态，提升全面健康状况与生活质量，并利于进一步调节凝血功能，控制血栓形成和炎症反应。

Objective To explore the clinical efficacy of Xintong Oral Liquid combined with indobufen in treatment of angina pectoris in coronary heart disease. Methods Patients (122 cases) with angina pectoris in coronary heart disease in Hebei Petrochina Central Hospital from May 2023 to October 2024 were divided into control group and treatment group according to random number table method, with 61 cases in each group. Patients in the control group were po administered with Indobufen Tablets, 0.1 g/time, twice daily. Patients in the treatment group were po administered with Xintong Oral Liquid on the basis of the control group after meals, 10 mL/time, three times daily. Patients in two groups were treated for 4 weeks. After treatment, the clinical evaluations were evaluated, and the frequency of colic episodes, pain VAS score, duration of episodes, ECG ST-T improvement rate, blood stasis syndrome scores and CHD-PRO, SAQ scores, the levels of TT, INR, PAR, D-D and hs-CRP in two groups before and after treatment were compared. Results After treatment, the total effective rate of treatment group was 95.08%, significantly higher than that of control group (83.61%, P < 0.05). After treatment, angina attack frequency, pain VAS score and attack duration in two groups were lower than those before treatment (P < 0.05), and treatment group was significantly lower than that in control group (P < 0.05). After treatment, the improvement rate of ECG ST-T in treatment group (85.25%) was significantly higher than that in control group (70.49%, P < 0.05). After treatment, the scores of blood stasis syndrome in two groups were lower than those before treatment, while the scores of CHD-PRO and SAQ were higher than those before treatment (P < 0.05), and the scores of treatment group were significantly better than those of control group (P < 0.05). After treatment, TT and INR in two groups were higher than before treatment, while PAR and plasma D-D and hs-CRP levels were lower than before treatment in the group (P < 0.05). After treatment, the coagulation indicators, PAR and plasma D-D, hs-CRP levels in the treatment group were significantly better than those in the control group (P < 0.05). Conclusion Xintong Oral Liquid combined with indobufen in treatment of coronary heart disease angina pectoris is safe. It can effectively relieve patients' angina symptoms, improve blood stasis, improve overall health status and quality of life, and help to further regulate coagulation function and control thrombosis. and inflammatory response.

R972

廊坊市科技支撑计划项目（2023013035）